← Eichor
Study identifier: NCT06258304 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Condition: Advanced or Metastatic Solid Tumor Malignancies  ·  Sponsor: GigaGen, Inc.

PhasePhase 1
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.

This description comes directly from the study's public registry record.

Talk to the study team

James Gulley  ·  888-624-1937  ·  ncimo_referrals@mail.nih.gov

Always discuss trial participation with your own doctor first.

Locations (1)

National Cancer InstituteBethesda, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06258304